Cycurion (NASDAQ:CYCU – Get Free Report) and Black Titan (NASDAQ:BTTC – Get Free Report) are both small-cap technology companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, risk, earnings and profitability.
Institutional & Insider Ownership
6.6% of Cycurion shares are owned by institutional investors. 4.6% of Cycurion shares are owned by company insiders. Comparatively, 0.7% of Black Titan shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Analyst Recommendations
This is a summary of recent ratings for Cycurion and Black Titan, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cycurion | 1 | 1 | 1 | 0 | 2.00 |
| Black Titan | 1 | 0 | 0 | 0 | 1.00 |
Cycurion presently has a consensus target price of $56.00, suggesting a potential upside of 2,492.59%. Given Cycurion’s stronger consensus rating and higher probable upside, research analysts plainly believe Cycurion is more favorable than Black Titan.
Risk & Volatility
Cycurion has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500. Comparatively, Black Titan has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500.
Earnings & Valuation
This table compares Cycurion and Black Titan”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cycurion | $15.13 million | 0.46 | -$23.67 million | ($24.64) | -0.09 |
| Black Titan | $180,000.00 | 21.93 | -$4.71 million | ($2.95) | -0.12 |
Black Titan has lower revenue, but higher earnings than Cycurion. Black Titan is trading at a lower price-to-earnings ratio than Cycurion, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Cycurion and Black Titan’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cycurion | -98.83% | -98.55% | -46.19% |
| Black Titan | N/A | N/A | N/A |
About Cycurion
Cycurion is a global leading provider of Network Communications and Information Technology Security Solutions. Our mission is to develop and deliver world-class, cutting-edge solutions for our clients, regardless of size or complication, expressly optimizing your IT environment to meet the business need and to keep projects on track and on budget.
About Black Titan
Titan Pharmaceuticals, Inc. is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.
Receive News & Ratings for Cycurion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cycurion and related companies with MarketBeat.com's FREE daily email newsletter.
